Novel approaches to retinal drug delivery

Expert Opinion on Drug Delivery

Volumn 4, Issue 4, 2007, Pages 371-388

  Janoria, Kumar G ^a   Gunda, Sriram ^a   Boddu, Sai H S ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; APTAMER; AZATHIOPRINE; BROMOCRIPTINE; CEPHALOSPORIN DERIVATIVE; CHLORAMBUCIL; CIDOFOVIR; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; FLUOROURACIL; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MICROSPHERE; MONOCLONAL ANTIBODY; NANOPARTICLE; OLIGONUCLEOTIDE; PENICILLIN G; PEPTIDE; PRODRUG; RNA; STEROID; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

BIODEGRADABLE IMPLANT; BLOOD RETINA BARRIER; DERIVATIZATION; DIABETIC MACULAR EDEMA; DIFFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSPORT; ENDOPHTHALMITIS; ENDOTHELIUM CELL; EYE DISEASE; GEL; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; IONTOPHORESIS; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT COMPLIANCE; PIGMENT EPITHELIUM; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS; REVIEW; TIGHT JUNCTION; ULTRASOUND; UNSPECIFIED SIDE EFFECT; UVEITIS; VITREORETINOPATHY;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-AQUEOUS BARRIER; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; RETINA; VITREOUS BODY;

EID: 34547870971     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.4.371     Document Type: Review

References (192)

1. CUNNINGHAM ET Jr, MARGOLIS TP: Ocular manifestations of HIV infection. N. Engl. J. Med. (1998) 339:236-244.
2. MASUR H, WHITCUP SM, CARTWRIGHT C, POLIS M, NUSSENBLATT R: Advances in the management of AIDS-related cytomegalovirus retinitis. Ann. Intern. Med. (1996) 125:126-136.
3. + T lymphocytes. J. Exp. Med. (1989) 169:1199-1212.
4. CROWE SM, CARLIN JB, STEWART KI, LUCAS CR, HOY JF: Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J. Acquir. Immune. Defic. Syndr. (1991) 4:770-776.
5. JACOBSON MA, ZEGANS M, PAVAN PR et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet (1997) 349:1443-1445.
6. YOUNG RW: Pathophysiology of age-related macular degeneration. Surv. Ophthalmol. (1987) 31:291-306.
7. KLEIN R, KLEIN BE, MOSS SE, DAVIS MD, DEMETS DL: The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology (1984) 91:1464-1474.
8. LOPES DE FARIA JM, JALKH AE, TREMPE CL, MCMEEL JW: Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol. Scand. (1999) 77:170-175.
9. AROCA PR, SALVAT M, FERNANDEZ J, MENDEZ I: Risk factors for diffuse and focal macular edema. J. Diabet. Complications (2004) 18:211-215.
10. PARK CH, JAFFE GJ, FEKRAT S: Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retina] vein occlusion. Am. J. Ophthalmol. (2003) 136:419-425.
11. CEKIC O, CHANG S, TSENG JJ et al.: Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina (2005) 25:846-850.
12. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology (1983) 90:121-125.
13. PASTOR JC: Proliferative vitreoretinopathy: an overview. Surv. Ophthalmol. (1998) 43:3-18.
14. KON CH, ASARIA RH, OCCLESTON NL, KHAW PT, AYLWARD GW: Risk factors for prolifarative vitreoretinopathy after primary vitrectomy: a prospective study. Br. J. Ophthalmol. (2000) 84:506-511.
15. FOSTER RE, MEYERS SM: Recurrent retinal detachment more than 1 year after reattachment. Ophthalmology (2002) 109:1821-1827.
16. ASARIA RH, KON CH, BUNCE C et al.: How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology (2001) 108:1184-1186.
17. TOGNETTO D, MINUTOLA D, SANGUINETTI G, RAVALICO G: Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology (2005) 112:1574.
18. DUMAS C, ONNET M: Choroidal detachment associated with rhegmatogenous retinal detachment: a risk factor for postoperative PVR? J. Fr. Ophtalmol. (1996) 19:455-463.
19. ASARIA RH, KON CH, BUNCE C, CHARTERIS DG, WONG D, KHAW PT, AYLWARD GW: Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology (2001) 108:1179-1183.
20. CHARTERIS DG, SETHI CS, LEWIS GP, FISHER SK: Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (2002) 16:369-374.
21. FORRESTER JV: Endogenous posterior uveitis. Br. J. Ophthalmol. (1990) 74:620-623.
22. TOWLER HM, LIGHTMAN S: Sympathetic ophthalmia. Int. Ophthalmol. Clin. (1995) 35:31-42.
23. JABS DA, JOHNS CJ: Ocular involvement in chronic sarcoidosis. Am. J. Ophthalmol. (1986) 102:297-301.
24. RIORDAN-EVA P, LIGHTMAN S: Orbital floor steroid injections in the treatment of uveitis. Eye (1994) 8(Part 1):66-69.
25. LIGHTMAN S: Use of steroids and immunosuppressive drugs in the management of posterior uveitis. Eye (1991) 5(Part 3):294-232.
26. HEMADY R, TAUBER J, FOSTER CS: Immunosuppressive drugs in immune and inflammatory ocular disease. Surv. Ophthalmol. (1991) 35:369-385.
27. SHAH SS, LOWDER CY, SCHMITT MA, WILKE WS, KOSMORSKY GS, MEISLER DM: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology (1992) 99:1419-1423.
28. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am. J. Ophthalmol. (1993) 115:575-582.
29. BLOOM JN, PALESTINE AG: The diagnosis of cytomegalovirus retinitis. Ann. Intern. Med. (1988) 109:963-969.
30. PEPOSE JS, HOLLAND GN, NESTOR MS, COCHRAN AJ, FOOS RY: Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology (1985) 92:472-484.
31. MUSCH DC,MARTIN DF, GORDON JF, DAVIS MD, KUPPERMANN BD: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N. Engl. J. Med. (1997) 337:83-90.
32. CUNHA-VAZ J: The blood-ocular barriers. Surv. Ophthalmol. (1979) 23:279-296.
33. CUNHA-VAZ JG: The blood-retinal barriers. Doc. Ophthalmol. (1976) 41:287-327.
34. STEUER H, JAWORSKI A, ELGER B et al.: Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest. Ophthalmol. Vis. Sci. (2005) 46:1047-1053.
35. AUKUNURU JV, SUNKARA G, BANDI N, THORESON WB, KOMPELLA UB: Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. (2001) 18:565-572.
36. KENNEDY BG, MANGINI NJ: P-glycoprotein expression in human retinal pigment epithelium. Mol. Vis. (2002) 8:422-430.
37. GREENWOOD J: Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro. J. Neuroimmunol. (1992) 39:123-132.
38. GEROSKI DH, EDELHAUSER HF: Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. (2000) 41:961-964.
39. HUGHES PM, OLEJNIK O, CHANG-LIN JE, WILSON CG: Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. (2005) 57:2010-2032.
40. BOURLAIS CL, ACAR L, ZIA H, SADO PA, NEEDHAM T, LEVERGE R: Ophthalmic drug delivery systems - recent advances. Prog. Retin Eye Res. (1998) 17:33-58.
41. AHMED I, PATTON TF: Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. (1985) 26:584-587.
42. BILL A: The drainage of albumin from the uvea. Exp. Eye Res. (1964) 75:179-187.
43. CHAPMAN JM, CHEEKS L, GREEN K: Interactions of benzalkonium chloride with soft and hard contact lenses. Arch. Ophthalmol. (1990) 108:244-246.
44. KAUR IP, KANWAR M: Ocular preparations: the formulation approach. Drug Dev. Ind. Pharm. (2002) 28:473-493.
45. LALEZARI JP, STAGG RJ, KUPPERMANN BD et al.: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. (1997) 126:257-263.
46. MOCHIZUKI M, IKEDA E, YOSHIMURA K et al.: Treatment of cytomegalovirus retinitis in AIDS with an intraocular sustained-release ganciclovir implant. Nippon Ganka Gakkai Zasshi (1998) 102:515-521.
47. BARZA M: Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation. Scand. J. Infect. Dis. Suppl. (1978):151-159.
48. TAYANITHI P: Treatment of cytomegalovirus retinitis in acquired immunodeficiency syndrome with intravitreal ganciclovir implant. J. Med. Assoc. Thai. (2001) 84(Suppl. 1):S142-S147.
49. MONTERO MC, PASTOR M, BUENESTADO C, LLUCH A, ATIENZA M: Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS. Ann. Pharmacother. (1996) 30:717-723.
50. LOPEZ-CORTES LF, PASTOR-RAMOS MT, RUIZ-VALDERAS R et al.: Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. (2001) 42:1024-1028.
51. CHENG L, HOSTETLER KY, LEE J et al.: Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest. Ophthalmol. Vis. Sci. (2004) 45:4138-4144.
52. FISHER JP, CIVILETTO SE, FORSTER RK: Toxicity, efficacy, and clearance of intravitreally injected of cefazolin. Arch. Ophthalmol. (1982) 100:650-652.
53. IYER MN, HE F, WENSEL TG, MIELER WF, BENZ MS, HOLZ ER: Intravitreal clearance of moxifloxacin. Trans. Am. Ophthalmol. Soc. (2005) 103:76-81; discussion 81-73.
54. BARZA M, LYNCH E, BAUM JL: Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits. Arch. Ophthalmol. (1993) 111:121-125.
55. KISHORE K, CONWAY MD, PEYMAN GA: Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg. Lasers (2001) 32:183-192.
56. EL-MASSRY A, MEREDITH TA, AGUILAR HE et al.: Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am. J. Ophthalmol. (1996) 122:684-689.
57. KIM H, CSAKY KG, GRAVLIN L et al.: Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 26:523-530.
58. KIM H, CSAKY KG, CHAN CC et al.: The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. (2006) 82:760-766.
59. HUGHES MS, SANG DN: Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg. Lasers Imaging (2006) 37:446-454.
60. MARMOR MF, NEGI A, MAURICE DM: Kinetics of macromolecules injected into the subretinal space. Exp. Eye Res. (1985) 40:687-696.
61. GHATE D, EDELHAUSER HF: Oaular drug delivery. Expert Opin. Drug Deliv. (2006) 3:275-287.
62. MAURICE D: Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. (2001) 17:393-401.
63. BAUM J, PEYMAN GA, BARZA M: Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv. Ophthalmol. (1982) 26:204-206.
64. CAMPOCHIARO PA, CONWAY BP: Aminoglycoside toxicity - a survey of retinal specialists. Implications for ocular use. Arch. Ophthalmol. (1991) 109:946-950.
65. MARTIN DF, SIERRA-MADERO J, WALMSLEY S et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. (2002) 346:1119-1126.
66. VELEZ G, WHITCUP SM: New developments in sustained release drug delivery for the treatment of intraocular disease. Br. J. Ophthalmol. (1999) 83:1225-1229.
67. AUSAYAKHUN S, YUVAVES P, NGAMTIPHAKOM S, PRASITSILP J: Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J. Med. Assoc. Thai. (2005) 88(Suppl. 9):S15-S20.
68. BAUDOUIN C, CHASSAIN C, CAUJOLLE C, GASTAUD P: Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica (1996) 210:329-335.
69. FUJINO Y, NAGATA Y, MIYOSHI M et al.: Intravitreal injection of ganciclovir in AIDS patients with cytomegalovirus retinitis. Nippon Ganka Gakkai Zasshi (1996) 100:634-640.
70. YOUNG S, MCCLUSKEY P, MINASSIAN DC et al.: Retinal detachment in cytomegalovirus retinitis: intravenous versus intravitreal therapy. Clin. Exp. Ophthalmol. (2003) 31:96-102.
71. HYNDIUK RA, REAGAN MG: Radioactive depot-corticosteroid penetration into monkey ocular tissue. I. Retrobulbar and systemic administration. Arch. Ophthalmol. (1968) 80:499-503.
72. TRIVEDI H, TODKAR H, ARBHAVE V. BHATIA P: Ocular anaesthesia for cataract surgery. Lancet(2003) 3:1312-1313, 1319.
73. EBNER R, DEVOTO MH, WEIL D et al.: Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br. J. Ophthalmol. (2004) 88:1380-1386.
74. VAN DEN BERG AA: An audit of peribulbar blockade using 15 mm, 25 mm and 37.5 mm needles, and sub-Tenon's injection. Anaesthesia (2004) 59:775-780.
75. RIPART J, LEFRANT JY, DE LA COUSSAYE JE, PRAT-PRADAL D, VIVIEN B, ELEDJAM JJ: Peribulbar versus retrobulbar anesthesia far ophthalmic surgery: an anatomical comparison of extraconal and intraconal injections. Anesthesiology (2001) 94:56-62.
76. WATKINS R, BEIGI B, YATES M, CHANG B, LINARDOS E: Intraocular pressure and pulsatile ocular blood flow after retrobulbar and peribulbar anaesthesia. Br. J. Ophthalmol. (2001) 85:796-798.
77. DAVIS DB II, MANDEL MR: Efficacy and complication rate of 16,224 consecutive peribulbar blocks. A prospective multicenter study. J. Cataract Refract Surg. (1994) 20:327-337.
78. KLEIN ML, JAMPOL LM, CONDON PI, RICE TA, SERJEANT GR: Central retinal artery occlusion without retrobulbar hemorrhage after retrobulbar anesthesia. Am. J. Ophthalmol. (1982) 93:573-577.
79. MORGAN JP, CLEARKIN LG: Rapid onset of ptosis indicates accurate intraconal placement during retrobulbar anaesthetic injection. Br. J. Ophthalmol. (2001) 85:363-365.
80. ROMAN SJ, CHONG SIT, DA, BOUREAU CM, AUCLIN FX, ULLERN MM: Sub-Tenon's anaesthesia: an efficient and safe technique. Br. J. Ophthalmol. (1997) 81:673-676.
81. WYLIE J, HENDERSON M, DOYLE M, HICKEY-DWYER M: Persistent binocular diplopia following cataract surgery: aetiology and management. Eye (1994) 8(Part 5):543-532.
82. CANAVAN KS, DARK A, GARRIOCH MA: Sub-Tenon's administration of local anaesthetic: a review of the technique. Br. J. Anaesth. (2003) 90:787-793.
83. KIM TW, LINDSEY JD, AIHARA M, ANTHONY TL, WEINREB RN: Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. (2002) 43: 1809-1816.
84. AMBATI J, GRAGOUDAS ES, MILLER JW et al.: Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. (2000) 41:1186-1191.
85. BITO LZ, BAROODY RA: The penetration of exogenous prostaglandin and arachidonic acid into, and their distribution within, the mammalian eye. Curr. Eye Res. (1981) 1:659-669.
86. WEIJTENS O, SCHOEMAKER RC, LENTJES EG, ROMIJN FP, COHEN AF, VAN MEURS JC: Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology (2000) 107:1932-1938.
87. ZIGNANI M, EINMAHL S, BAEYENS V et al.: A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release. Eur. J. Pharm. Biopharm. (2000) 50:251-255.
88. GEROSKI DH, EDELHAUSER HF: Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. (2001) 52:37-48.
89. MAINARDES RM, SILVA LP: Drug delivery systems: past, present, and future. Curr. Drug Targets (2004) 5:449-455.
90. FISHMAN PH, PEYMAN GA, LESAR T: Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Invest. Ophthalmol. Vis. Sci. (1986) 27:1103-1106.
91. ZENG S, HU C, WEI H et al.: Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology (1993) 100:1640-1644.
92. LIU KR, PEYMAN GA, KHOOBEHI B, ALKAN H, FISCELLA R: Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. Ophthalmology (1987) 94:1155-1159.
93. PEYMAN GA, KHOOBEHI B, TAWAKOL M et al.: Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina (1987) 7:227-229.
94. ALGHADYAN AA, PEYMAN GA, KHOOBEHI B, LIU KR: Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int. Ophthalmol. (1988) 12:105-107.
95. ALGHADYAN AA, PEYMAN GA, KHOOBEHI B, MILNER S, LIU KR: Liposome-bound cyclosporine: clearance after intravitreal injection. Int. Ophthalmol. (1988) 12:109-112.
96. PEYMAN GA, GANIBAN GJ: Delivery systems for intraocular routes. Adv. Drug Deliv. Rev. (1995) 16:107-112.
97. AKULA SK, MA PE, PEYMAN GA et al.: Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br. J. Ophthalmol. (1994) 78:677-680.
98. DIAZ-LLOPIS M, MARTOS MJ, ESPANA E et al.: Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial. Doc. Ophthalmol. (1992) 82:297-305.
99. PEYMAN GA, SCHULMAN JA, KHOOBEHI B, ALKAN HM, TAWAKOL ME, MANI H: Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina (1989) 9:232-236.
100. COLTHURST MJ, WILLIAMS RL, HISCOTT PS, GRIERSON I: Biomaterials used in the posterior segment of the eye. Biomaterials (2000) 21:649-665.
101. LE BOURLAIS C, CHEVANNE F, ROPERT P et al.: Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits. J. Microencapsul. (1996) 13:473-480.
102. OGURA' Y: Drug delivery to the posterior segments of the eye. Adv. Drug Deliv. Rev. (2001) 52:1-3.
103. CHENG L, HOSTETLER KY, CHAIDHAWANGUL S et al.: Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest. Ophthalmol. Vis. Sci. (2000) 41:1523-1532.
104. BOCHOT A, COUVREUR P, FATTAL E: Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin Eye Res. (2000) 19:131-147.
105. OGURA Y, GURAN T, SHAHIDI M, MORI MT, ZEIMER RC: Feasibility of targeted drug delivery to selective areas of the retina. Invest. Ophthalmol. Vis. Sci. (1991) 32:2351-2356.
106. ZEIMER RC, KHOOBEHI B, NIESMAN MR, MAGIN RL: A potential method for local drug and dye delivery in the ocular vasculature. Invest. Ophthalmol. Vis. Sci. (1988) 29:1179-1183.
107. DESHPANDE AA, HELLER J, GURNY R: Bioerodible polymers for ocular drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1998) 15:381-420.
108. HELLER J: Ocular delivery using poly(ortho esters). Adv. Drug Deliv. Rev. (2005) 57:2053-2062.
109. KIMURA H, OGURA Y: Biodegradable polymers for ocular drug delivery. Ophthalmologica (2001) 215:143-155.
110. GIORDANO GG, CHEVEZ-BARRIOS P, REFOJO MF, GARCIA CA: Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Curr. Eye Res. (1995) 14:761-768.
111. KHOOBEHI B, STRADTMANN MO, PEYMAN GA, ALY OM: Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. (1991) 22:175-180.
112. MORITERA T, OGURA Y, YOSHIMURA N, HONDA Y, WADA R, HYON SH, IKADA Y: Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. (1992) 33:3125-3130.
113. GIORDANO GG, REFOJO MF, ARROYO MH: Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Vis. Sci. (1993) 34:2743-2751.
114. MORITERA T, OGURA Y, HONDA Y, WADA R, HYON SH, IKADA Y: Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. (1991) 32:1785-1790.
115. PEYMAN GA, CONWAY M, KHOOBEHI B, SOIKE K: Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol. (1992) 16:109-113.
116. VELOSO AA Jr, ZHU Q, HERRERO-VANRELL R, REFOJO MF: Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. (1997) 38:665-675.
117. HE Y, WANG JC, LIU YL, MA ZZ, ZHU XA, ZHANG Q: Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. J. Ocul. Pharmacol. Ther. (2006) 22:121-131.
118. DUVVURI S, JANORIA KG, MITRA AK: Development of a novel formulation containing poly (D,L-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J. Control. Release (2005) 108:282-293.
119. DUVVURI S, JANORIA KG, PAL D, MITRA AK: Controlled delivery of ganciclovir to the retina with drug loaded PLGA microspheres dispersed in PLGA-PEG-PLGA gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J. Ocul. Pharmacol. Ther. (2007) 23(3):264-274.
120. MERODIO M, IRACHE JM, VALAMANESH F, MIRSHAHI M: Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials (2002) 23:1587-1594.
121. DE KOZAK Y, ANDRIEUX K, VILLARROYA H et al.: Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. (2004) 34:3702-3712.
122. BOURGES JL, GAUTIER SE, DELIE F et al.: Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. (2003) 44:3562-3569.
123. SAKURAI E, OZEKI H, KUNOU N, OGURA Y: Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. (2001) 33:31-36.
124. SANBORN GE, ANAND R, TORTI RE et al.: Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch. Ophthalmol. (1992) 110:188-195.
125. HASHIZOE M, OGURA Y, TAKANASHI T, KUNOU N, HONDA Y, IKADA Y: Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr. Eye Res. (1997) 16:633-639.
126. KIMURA H, OGURA Y, HASHIZOE M, NISHIWAKI H, HONDA Y, IKADA Y: A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest. Ophthalmol. Vis. Sci. (1994) 35:2815-2819.
127. LIM JI, WOLITZ RA, DOWLING AH, BLOOM HR, IRVINE AR, SCHWARTZ DM: Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. (1999) 127:288-293.
128. JAFFE GJ, BEN-NUN J, GUO H, DUNN JP, ASHTON P: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology (2000) 107:2024-2033.
129. JAFFE GJ, PEARSON PA, ASHTON P: Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina (2000) 20:402-403.
130. JAFFE GJ, YANG CS, WANG XC, COUSINS SW, GALLEMORE RP, ASHTON P: Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology (1998) 105:46-56.
131. JAFFE GJ, MCCALLUM RM, BRANCHAUD B, SKALAK C, BUTUNER Z, ASHTON P: Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology (2005) 112:1192-1198.
132. YANG CS, KHAWLY JA, HAINSWORTH DP et al.: An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. (1998) 116:69-77.
133. OKABE K, KIMURA H, OKABE J, KATO A, KUNOU N, OGURA Y: Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. (2003) 44:2702-2707.
134. KUNOU N, OGURA Y, HASHIZOE M, HONDA Y, HYON S, IKADA Y: Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release (1995) 37:143-215.
135. KUNOU N, OGURA Y, YASUKAWA T et al.: Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release (2000) 68:263-271.
136. SAKURAI E, MATSUDA Y, OZEKI H, KUNOU N, NAKAJIMA K, OGURA Y: Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. (2001) 42:2043-2048.
137. YASUKAWA T, KIMURA H, KUNOU N et al.: Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch. Clin. Exp. Ophthalmol. (2000) 238: 186-190.
138. MIYAMOTO H, OGURA Y, HASHIZOE M, KUNOU N, HONDA Y, IKADA Y: Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. (1997) 16:930-935.
139. HASHIZOE M, OGURA Y, KIMURA H et al.: Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch. Ophthalmol. (1994) 112:1380-1384.
140. HASHIZOE M, OGURA Y, TAKANASHI T, KUNOU N, HONDA Y, IKADA Y: Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr. Eye Res. (1995) 14:473-477.
141. RUBSAMEN PE, DAVIS PA, HERNANDEZ E, O'GRADY GE, COUSINS SW: Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. (1994) 112:407-413.
142. ZHOU T, LEWIS H, FOSTER RE, SCHWENDEMAN SP: Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release (1998) 55:281-295.
143. SAKURAI E, NOZAKI M, OKABE K, KUNOU N, KIMURA H, OGURA Y: Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Vis. Sci. (2003) 44:4845-4852.
144. MORITA Y, OHTORI A, KIMURA M AND TOJO K: Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol. Pharm. Bull. (1998) 21:188-190.
145. OKABE J, KIMURA H, KUNOU N, OKABE K, KATO A, OGURA Y: Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. (2003) 44:740-744.
146. DIAS CS, ANAND BS, MITRA AK: Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J. Pharm. Sci. (2002) 91:660-668.
147. DUN Y, MYSONA B, ITAGAKI S, MARTIN-STUDDARD A, GANAPATHY V, SMITH SB: Functional and molecular analysis of D-serine transport in retinal Muller cells. Exp. Eye Res. (2007) 84:191-199.
148. GERHART DZ, LEINO RL, DREWES LR: Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience (1999) 92:367-375.
149. KANSARA V, LUO S, BALASUBRAHMANYAM B, PAL D, MITRA AK: Biotin uptake and cellular translocation in human derived retinoblastoma cell line (Y-79): a role of hSMVT system. Int. J. Pharm. (2006) 312:43-52.
150. KANSARA V, PAL D, JAIN R, MITRA AK: Identification and functional characterization of riboflavin transporter in human-derived retinoblastoma cell line (Y-79): mechanisms of cellular uptake and translocation. J. Ocul. Pharmacol. Ther. (2005) 21:275-287.
151. WIESSNER M, FLETCHER EL, FISCHER F, RAUEN T: Localization and possible function of the glutamate transporter, EAAC1, in the rat retina. Cell Tissue Res. (2002) 310:31-40.
152. LEE VH: Membrane transporters. Eur. J. Pharm. Sci. (2000) 11 (Suppl. 2):S41-S50.
153. ADIBI SA: Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Am. J. Physiol. (1997) 272:E723-E736.
154. +-oligopeptide cotransporter hPEPT1. J. Physiol. (2006) 574:149-166.
155. NOVOTNY A, XIANG J, STUMMER W, TEUSCHER NS, SMITH DE, KEEP RF: Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem. (2000) 75:321-328.
156. ANAND BS, PATEL J, MITRA AK: Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J. Pharmacol. Exp. Ther. (2003) 304:781-791.
157. MAJUMDAR S, NASHED YE, PATEL K et al.: Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J. Ocul. Pharmacol. Ther. (2005) 21:463-474.
158. ANAND BS, MITRA AK: Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. (2002) 19:1194-1202.
159. ATLURI H, ANAND BS, PATEL J, MITRA AK: Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp. Eye Res. (2004) 78:815-822.
160. MAJUMDAR S, KANSARA V, MITRA AK: Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J. Ocul. Pharmacol. Ther. (2006) 22:231-241.
161. ANAND BS, KATRAGADDA S, NASHED YE, MITRA AK: Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr. Eye Res. (2004) 29:153-166.
162. +-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. Mol. Pharm. (2004) 1:338-346.
163. BONEN A: The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur. J. Appl. Physiol. (2001) 86:6-11.
164. HALESTRAP AP, PRICE NT: The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J. (1999) 343 (Part 2):281-299.
165. LIN RY, VERA JC, CHAGANTI RS, GOLDE DW: Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J. Biol. Chem. (1998) 273:28959-28965.
166. PHILP NJ, YOON H, GROLLMAN EF: Monocarboxylate transporter MCT1 is located in the apical membrane and MCT3 in the basal membrane of rat RPE. Am. J. Physiol. (1998) 274:R1824-R1828.
167. HOSOYA K, KONDO T, TOMI M, TAKANAGA H, OHTSUKI S, TERASAKI T: MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm. Res. (2001) 18:1669-1676.
168. TSUJI A,TAMAI I, NAKANISHI M, TERASAKI T, HAMANO S: Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. J. Pharm. Pharmacol. (1993) 45:996-998.
169. LI YH, ITO K, TSUDA Y, KOHDA R, YAMADA H, ITOH T: Mechanism of intestinal absorption of an orally active beta-lactam prodrug: uptake and transport of carindacillin in Caco-2 cells. J. Pharmacol. Exp. Ther. (1999) 290:958-964.
170. CHANCY CD, KEKUDA R, HUANG W et al.: Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J. Biol. Chem. (2000) 275:20676-20684.
171. KANSARA V, MITRA AK: Evaluation of an ex vivo model implication for carrier-mediated retinal drug delivery. Curr. Eye Res. (2006) 31:415-426.
172. DUVVURI S, GANDHI MD, MITRA AK: Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr. Eye Res. (2003) 27:345-353.
173. KANIKKANNAN N: Iontophoresis-based transdermal delivery systems. Bio. Drugs (2002) 16:339-347.
174. SIMS SM, HIGUCHI WI, SRINIVASAN V: Skin alteration and convective solvent flow effects during ionrophoresis. II. Monovalent anion and cation transport across human skin. Pharm. Res. (1992) 9:1402-1409.
175. SINGH J, MAIBACH HI: Topical iontophoretic drug delivery in vivo: historical development, devices and future perspectives. Dermatology (1993) 187:235-238.
176. PHIPPS JB, PADMANABHAN RV, LATTIN GA: Iontophoretic delivery of model inorganic and drug ions. J. Pharm. Sci. (1989) 78:365-369.
177. KARI B: Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes (1986) 35:217-221.
178. D'Emanuele A, STANIFORTH JN: An electrically modulated drug delivery device. III. Factors affecting drug stability during electrophoresis. Pharm. Res. (1992) 9:312-315.
179. ZHU H, LI SK, PECK KD, MILLER DJ, HIGUCHI WI: Improvement on conventsonal constant current DC iontophoresis: a study using constant conductance AC iontophoresis. J. Control. Release (2002) 82:249-261.
180. KALIA YN, NAIK A, GARRISON J, GUY RH: Iontophoretic drug delivery. Adv. Drug Deliv. Rev. (2004) 56:619-658.
181. WELSH RG, FOWLER JE, SHAPLAND JE: Iontophoretic drug delivery system. Semin. Interv. Cardiol. (1996) 1:40-42.
182. BURNETTE RR, ONGPIPATTANAKUL B: Characterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J. Pharm. Sci. (1988) 77:132-137.
183. FISCHER GA, PARKINSON TM, SZLEK MA: OcuPhor - the future of ocular drug delivery. Drug Deliv. Technol. (2002) 2:50-52.
184. ELJARRAT-BINSTOCK E, RAISKUP F, STEPENSKY D, DOMB AJ, FRUCHT-PERY J: Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest. Ophthalmol. Vis. Sci. (2004) 45:2543-2548.
185. VOLLMER DL, SZLEK MA, KOLB K, LLOYD LB, PARKINSON TM: In vivo transscleral iontophoresis of amikacin to rabbit eyes. J. Ocul. Pharmacol. Ther. (2002) 18:549-558.
186. HOBDEN JA, ROOTMAN DS, O'CALLAGHAN RJ, HILL JM: Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas. Antimicrob. Agents Chemother. (1988) 32:978-981.
187. BARZA M, PECKMAN C, BAUM J: Trsnsscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology (1986) 93:133-139.
188. BATHEJA P, THAKUR R, MICHNIAK B: Transdermal iontophoresis. Expert Opin. Drug Deliv. (2006) 3:127-138.
189. MYLES ME, NEUMANN DM, HILL JM: Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. (2005) 57:2063-2079.
190. GRIFFIN JE, TOUCHSTONE JC: Ultrasonic movement of cortisol into pig tissues. I. Movement into skeletal muscle. Am. J. Phys. Med. (1963) 42:77-85.
191. ZDERIC V, VAEZY S, MARTIN RW AND CLARK JI: Ocular drug delivery using 20-kHz ultrasound. Ultrasound Med. Biol. (2002) 28:823-829.
192. ZDERIC V, CLARK JI, MARTIN RW AND VAEZY S: Ultrasound-enhanced transcorneal drug delivery. Cornea (2004) 23:804-811.